No annual revenue total was found in IMMUNOVANT, INC.'s SEC filings.
Immunovant, Inc. (IMVT) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$407.3 million.
Revenue
—
Net income (TTM)
$-538.22M
-20.3% vs year-ago TTM
Operating cash flow (TTM)
$-414.30M
+0.7% vs year-ago TTM
Free cash flow
$-407.32M
-8.1% vs prior year
EPS (TTM)
$-2.82
+0.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
205.31M
+20.1% vs prior year
Net cash
$902.04M
FY 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IMVT (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1764013
- Former names
- Health Sciences Acquisitions Corp (until Dec 20, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Mar 31, 2026 |
FY 2025 Mar 31, 2025 |
FY 2024 Mar 31, 2024 |
FY 2023 Mar 31, 2023 |
FY 2022 Mar 31, 2022 |
|---|---|---|---|---|---|
| Net income | -$505.6M | -$413.8M | -$259.3M | -$211.0M | -$156.7M |
| Diluted EPS | -$2.77 | -$2.73 | -$1.88 | -$1.71 | -$1.43 |
| Operating cash flow | -$407.3M | -$375.9M | -$214.2M | -$188.2M | -$106.1M |
| Free cash flow | -$407.3M | -$376.6M | -$214.6M | -$188.4M | -$106.4M |
| Total assets | $957.0M | $776.2M | $666.4M | $405.8M | $515.6M |
| Total liabilities | $104.4M | $68.8M | $48.6M | $43.3M | $45.7M |
| Stockholders' equity | $852.6M | $707.4M | $617.8M | $362.5M | $469.8M |
| Cash and investments | $902.1M | $714.0M | $635.4M | $376.5M | $493.8M |
| Total debt | $72,000 | $98,000 | $138,000 | $1.2M | $2.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Sep 3, 2026 | Sep 2, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| ARS | Annual report to shareholders | Jul 22, 2026 | Mar 31, 2026 |
| 10-K | Annual report | May 20, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 20, 2026 | May 20, 2026 |
All 648 Immunovant, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.